CN112423752A - C5a拮抗剂和ANCA相关性血管炎的剂量和疗效 - Google Patents

C5a拮抗剂和ANCA相关性血管炎的剂量和疗效 Download PDF

Info

Publication number
CN112423752A
CN112423752A CN201980038855.4A CN201980038855A CN112423752A CN 112423752 A CN112423752 A CN 112423752A CN 201980038855 A CN201980038855 A CN 201980038855A CN 112423752 A CN112423752 A CN 112423752A
Authority
CN
China
Prior art keywords
treatment
level
complement factor
administering
alvarazepam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980038855.4A
Other languages
English (en)
Chinese (zh)
Inventor
邓军
P·贝克
J·希尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CN112423752A publication Critical patent/CN112423752A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980038855.4A 2018-06-07 2019-06-06 C5a拮抗剂和ANCA相关性血管炎的剂量和疗效 Pending CN112423752A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
US62/682,013 2018-06-07
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Publications (1)

Publication Number Publication Date
CN112423752A true CN112423752A (zh) 2021-02-26

Family

ID=68764799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038855.4A Pending CN112423752A (zh) 2018-06-07 2019-06-06 C5a拮抗剂和ANCA相关性血管炎的剂量和疗效

Country Status (15)

Country Link
US (2) US11191756B2 (https=)
EP (1) EP3801519A4 (https=)
JP (2) JP2021527062A (https=)
KR (2) KR20260027358A (https=)
CN (1) CN112423752A (https=)
AU (1) AU2019282327B2 (https=)
BR (1) BR112020024842A2 (https=)
CA (1) CA3102403A1 (https=)
CL (1) CL2020003171A1 (https=)
IL (1) IL279188B2 (https=)
MA (1) MA52808A (https=)
MX (1) MX2020013166A (https=)
SG (1) SG11202011961YA (https=)
WO (1) WO2019236820A1 (https=)
ZA (1) ZA202007615B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
CN114867473A (zh) * 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20080188528A1 (en) 2006-12-22 2008-08-07 Biediger Ronald J Modulators of C3a receptor and methods of use thereof
RU2010138612A (ru) * 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
RS54998B1 (sr) * 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
WO2016166357A2 (en) 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEI SHI，: "Anti‑neutrophil cytoplasmic antibody‑associated vasculitis: prevalence, treatment, and outcomes", vol. 37, no. 11, pages 1779 - 1788, XP036343706, DOI: 10.1007/s00296-017-3818-y *
PIROW BEKKER ET AL.,: "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study", 《PLOS ONE》, vol. 11, no. 10, pages 1 - 19 *
U JAIN ET AL.,: "The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10", vol. 168, no. 2, pages 488 - 501, XP055407018, DOI: 10.1111/j.1476-5381.2012.02183.x *
李颖: "补体系统参与抗中性粒细胞胞浆抗体相关性 血管炎发病机制研究进展", vol. 26, no. 9, pages 864 - 866 *

Also Published As

Publication number Publication date
ZA202007615B (en) 2024-05-30
CA3102403A1 (en) 2019-12-12
MX2020013166A (es) 2021-03-29
JP2021527062A (ja) 2021-10-11
EP3801519A1 (en) 2021-04-14
AU2019282327A1 (en) 2021-01-07
MA52808A (fr) 2021-04-14
US11191756B2 (en) 2021-12-07
CL2020003171A1 (es) 2021-06-04
KR20210018906A (ko) 2021-02-18
AU2019282327B2 (en) 2025-04-24
EP3801519A4 (en) 2022-03-30
SG11202011961YA (en) 2020-12-30
US12350263B2 (en) 2025-07-08
WO2019236820A1 (en) 2019-12-12
IL279188B2 (en) 2026-04-01
US20220296576A1 (en) 2022-09-22
IL279188A (en) 2021-01-31
BR112020024842A2 (pt) 2021-03-02
US20190374524A1 (en) 2019-12-12
KR20260027358A (ko) 2026-02-27
IL279188B1 (en) 2025-12-01
JP2024114706A (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
EP4003327B1 (en) Compounds for use in the treatment of paroxysmal nocturnal haemoglobinuria (pnh)
JP7101413B2 (ja) 真菌感染症の治療方法
US12350263B2 (en) Dosing and effect of C5a antagonist with ANCA-associated vasculitis
US20130116324A1 (en) Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin
AU2011334617A2 (en) Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
JP2014169321A (ja) 嚢胞性疾患の治療のためのプリン誘導体
CN104224772A (zh) 一种包含丁苯酞和冰片的药物组合物及其应用
WO2024184784A1 (en) Use of myriocin as adjuvant in glaucoma surgery
CA3043103A1 (en) Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
RU2485956C2 (ru) Новая композиция для лечения побочных эффектов противораковой терапии
RU2835509C2 (ru) Дозирование и эффект c5a антагониста при anca-ассоциированном васкулите
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
WO2020201444A1 (en) Repurposing small molecules for senescence-related diseases and disorders
CN107106566A (zh) 晶状体硬化抑制剂
WO2019157085A2 (en) INHIBITION OF WNT/β-CATENIN SIGNALING IN THE TREATMENT OF OSTEOARTHRITIS
US9943497B2 (en) Pharmaceutical composition for preventing or treating pulmonary fibrosis
US20210308078A1 (en) New use of inhibitors of monoamine oxidase type b
KR20190109192A (ko) 푸니칼라진을 포함하는 par2 활성 억제용 조성물
KR20260023197A (ko) 세사민을 포함하는 아토피성 피부염의 개선 또는 치료용 조성물
TWI620566B (zh) 三萜混合物用以治療多發性硬化的用途
KR20250108710A (ko) 다발성 경화증의 치료 방법
CA2838832C (en) Pharmaceutical composition for preventing or treating pulmonary fibrosis
EP3010532A1 (en) Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
HK1223831A1 (en) Quaternary ammonium compound for use as an inhibitor of protein kinase c alpha
HK1169029A (en) Pharmaceutical composition for treating cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination